Drug Patents owned by Currax

1. Drug name - ONZETRA XSAIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8047202 CURRAX Nasal devices Jul, 2023

(8 months from now)

US8327844 CURRAX Nasal delivery method Oct, 2023

(11 months from now)

US9119932 CURRAX Nasal delivery device Apr, 2024

(1 year, 6 months from now)

US7975690 CURRAX Nasal devices Aug, 2025

(2 years from now)

US9108015 CURRAX Nasal delivery devices Sep, 2025

(2 years from now)

US8590530 CURRAX Nasal delivery devices Sep, 2025

(2 years from now)

US10124132 CURRAX Nasal delivery Mar, 2027

(4 years from now)

US10398859 CURRAX Nasal delivery devices Dec, 2027

(5 years from now)

US8875704 CURRAX Nasal administration Apr, 2028

(5 years from now)

US10722667 CURRAX Nasal administration Dec, 2028

(6 years from now)

US10076615 CURRAX Nasal delivery Jul, 2029

(6 years from now)

US8550073 CURRAX Nasal delivery Oct, 2029

(7 years from now)

US8899229 CURRAX Powder delivery devices Aug, 2030

(7 years from now)

US9649456 CURRAX Nasal administration Oct, 2030

(8 years from now)

US8978647 CURRAX Nasal delivery Dec, 2030

(8 years from now)

US10478574 CURRAX Nasal administration Nov, 2033

(11 years from now)

US10076614 CURRAX Nasal delivery devices Oct, 2034

(12 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Treatment: Method of drug delivery via the nasal cavity; Treatment of migraine via delivery of sumatriptan via the nasal cavity; acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device; acute treatment of migraine; Treatment of migraine via delivery of sumatriptan via the nasal cavity; acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device; method of delivering sumatriptan to a nasal cavity; Acute treatment of migraine; treatment of migraine via delivery of sumatriptan via the nasal cavity; acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device; Method of delivering sumatriptan to a nasal cavity

Dosage: POWDER;NASAL

More Information on Dosage
Strength Dosage Availability
EQ 11MG BASE POWDER;NASAL Prescription

2. Drug name - SILENOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9861607 CURRAX Methods of using low-dose doxepin for the improvement of sleep May, 2027

(4 years from now)

US10653662 CURRAX Methods of using low-dose doxepin for the improvement of sleep May, 2027

(4 years from now)

US10238620 CURRAX Methods of using low-dose doxepin for the improvement of sleep May, 2027

(4 years from now)

US9486437 CURRAX Methods of using low-dose doxepin for the improvement of sleep May, 2027

(4 years from now)

US9572814 CURRAX Methods of improving the pharmacokinetics of doxepin Jul, 2027

(4 years from now)

US11110074 CURRAX Methods of improving the pharmacokinetics of doxepin Jul, 2027

(4 years from now)

US10653660 CURRAX Methods of improving the pharmacokinetics of doxepin Jul, 2027

(4 years from now)

US7915307 CURRAX Methods of improving the pharmacokinetics of doxepin Aug, 2027

(4 years from now)

US11234954 CURRAX Low-dose doxepin for treatment of sleep disorders in elderly patients Jan, 2028

(5 years from now)

US11096920 CURRAX Low-dose doxepin formulations and methods of making and using the same Apr, 2028

(5 years from now)

US9907780 CURRAX Low-dose doxepin formulations and methods of making and using the same Apr, 2028

(5 years from now)

US10548871 CURRAX Low-dose doxepin formulations and methods of making and using the same Apr, 2028

(5 years from now)

US9107898 CURRAX Methods of using low-dose doxepin for the improvement of sleep May, 2028

(5 years from now)

US9532971 CURRAX Low-dose doxepin formulations and methods of making and using the same Jun, 2029

(6 years from now)

US8513299 CURRAX Methods of using low-dose doxepin for the improvement of sleep Sep, 2030

(7 years from now)

Drugs and Companies using DOXEPIN HYDROCHLORIDE ingredient

Treatment: Treatment of insomnia

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 3MG BASE TABLET;ORAL Prescription
EQ 6MG BASE TABLET;ORAL Prescription

3. Drug name - TREXIMET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7332183 CURRAX Multilayer dosage forms containing NSAIDs and triptans Oct, 2025

(2 years from now)

US7332183

(Pediatric)

CURRAX Multilayer dosage forms containing NSAIDs and triptans Apr, 2026

(3 years from now)

Drugs and Companies using NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE ingredient

Treatment: Treatment of migraine; acute treatment of migraine

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
60MG;EQ 10MG BASE TABLET;ORAL Discontinued
500MG;EQ 85MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.